Kadcyla (trastuzumab) 160 mg IV ROCHE Switzerland
Article:
R-7
In Stock
testimony
- Kadcyla® is used in patients with HER2-positive, unresectable locally or metastatic breast cancer as monotherapy after previous chemotherapy that included trastuzumab and a taxane drug (alone or in combination), or when the disease recurs during or within 6- months after completion of adjuvant therapy, which included trastuzumab and a drug from the taxane group (alone or in combination).
- 1330ct
- kadzila, kadzila,
-
Commercial name:Kadcyla
-
Сhemical name:Trastuzumab
-
Dosage:160 mg
-
Release form:Bottle
-
Производитель:Roche, Германия
No reviews yet